Skip to content
  • Tuesday, 27 October 2026
  • 11:27 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • MSD Strengthens Oncology Pipeline with Multi-Billion-Dollar Licensing Deal for Shanghai-Based SciBrunch Therapeutics KRAS Inhibitor SPR2015
Pharmaceutical R&D

MSD Strengthens Oncology Pipeline with Multi-Billion-Dollar Licensing Deal for Shanghai-Based SciBrunch Therapeutics KRAS Inhibitor SPR2015

Teuku Ryan Sep 30, 2026 0

In a strategic move to fortify its oncology portfolio against looming patent expirations, MSD—known as Merck & Co. in the…

Read More
Laboratory Automation & Robotics

Calderasib’s Real Innovation: Designed for Combinability and Potency Unlocks New Frontiers in KRAS-Mutated Cancers

Lana Keisha Jul 19, 2026 0

Merck’s latest investigational drug, calderasib, is not merely another entry into the burgeoning field of KRAS G12C inhibition; it represents…

Read More
Sandoz and mAbxience Forge Strategic Global Partnership to Develop and Commercialize Emicizumab Biosimilar for Haemophilia AExecutive War College 2026 to Spotlight AI, Workforce Solutions, and Financial Strategy for Clinical LabsThe Nanozymes Hypothesis Offers a Unified Framework for the Origin of Life on EarthThe Fine-Tuning Paradox: How Fundamental Physical Constants and Fluid Viscosity Dictate the Boundaries of Life in the Universe
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic ProportionsMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
Merck and Moderna’s cancer vaccine is customized for each patient’s tumorAn Unbiased Look at Google Gemini Omni: Features, Costs, and Market ComparisonESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial CancerLight-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
Lana Keisha Oct 27, 2026
Data Science & Bioinformatics
An Unbiased Look at Google Gemini Omni: Features, Costs, and Market Comparison
Evan Lee Salim Oct 27, 2026
Pharmaceutical R&D
ESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial Cancer
Teuku Ryan Oct 27, 2026
Advanced Materials Science
Light-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
Nila Kartika Wati Oct 27, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ